Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of mobile phase pH on liquid chromatography retention of mepartricin related compounds and impurities as support to the structural investigation by liquid chromatography-mass spectrometry.
J Pharm Biomed Anal
October 2022
Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy. Electronic address:
Mepartricin is a semisynthetic polyene macrolide with antifungal and anti-protozoal activities, and it is widely used for the treatment of benign prostatic hyperplasia. Mepartricin is produced by synthetic methyl esterification of the more toxic partricin, and its activity is due to a complex of related compounds. Among them, the main ones are mepartricin B and mepartricin A which are characterized by the presence of a primary and a secondary amine group, respectively.
View Article and Find Full Text PDFIpertrofan Revisited-The Proposal of the Complete Stereochemistry of Mepartricin A and B.
Molecules
September 2021
Department of Pharmaceutical Technology and Biochemistry and BioTechMed Centre, Faculty of Chemistry, Gdańsk University of Technology, Gabriela Narutowicza Str. 11/12, 80-233 Gdańsk, Poland.
Being a methyl ester of partricin, the mepartricin complex is the active substance of a drug called Ipertrofan (Tricandil), which was proven to be useful in treatment of benign prostatic hyperplasia and chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Nevertheless, no direct structural evidence on the stereochemistry of its components has been presented to date. In this contribution, we have conducted detailed, NMR-driven stereochemical studies on mepartricins A and B, aided by molecular dynamics simulations.
View Article and Find Full Text PDFPharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review.
BJU Int
April 2020
Family and Community Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Objective: To assess the effects of pharmacological therapies for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Patients And Methods: We performed a comprehensive search using multiple databases, trial registries, grey literature and conference proceedings with no restrictions on the language of publication or publication status. The date of the latest search of all databases was July 2019.
Chronic bacterial prostatitis and chronic pelvic pain syndrome.
BMJ Clin Evid
August 2015
Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, US.
Introduction: Chronic prostatitis can cause pain and urinary symptoms, and can occur either with an active infection (chronic bacterial prostatitis [CBP]) or with only pain and no evidence of bacterial causation (chronic pelvic pain syndrome [CPPS]). Bacterial prostatitis is characterised by recurrent urinary tract infections or infection in the prostate with the same bacterial strain, which often results from urinary tract instrumentation. However, the cause and natural history of CPPS are unknown and not associated with active infection.
View Article and Find Full Text PDFIdentification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library.
Antibiotics (Basel)
September 2015
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Lyme disease is a leading vector-borne disease in the United States. Although the majority of Lyme patients can be cured with standard 2-4 week antibiotic treatment, 10%-20% of patients continue to suffer from prolonged post-treatment Lyme disease syndrome (PTLDS). While the cause for this is unclear, persisting organisms not killed by current Lyme antibiotics may be involved.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!